Related Experiment Video
Updated: Jul 8, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
[Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma]
1Department of Biochemistry and Molecular Biology, School of Basic Medicine, Dali University, Dali 671000, China.
Abstract:
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, characterized by insidious onset, strong local invasiveness, short survival period, and poor prognosis. Clinical diagnosis is of paramount importance for the treatment and prognosis of MPM. Currently, the gold standard for diagnosing MPM is the results of histopathological examinations. Immunohistochemistry (IHC) is an effective auxiliary method in pathological diagnosis. Preliminary examinations can use two positive markers and two negative markers to distinguish pleural metastatic tumors, with additional antibodies selected based on differential diagnosis. The combined use of IHC markers plays a crucial role in the differential diagnosis between MPM and other tumors. This article primarily introduces commonly used IHC markers in MPM and the research progress of novel IHC markers in screening and differential diagnosis, aiming to provide reference for the clinical diagnosis and treatment of MPM.
Insights
Malignant pleural mesothelioma (MPM) diagnosis relies on histopathology. Immunohistochemistry (IHC) aids in distinguishing MPM from other tumors using specific markers, improving clinical outcomes.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Context:
- Malignant pleural mesothelioma (MPM) presents with insidious onset, local invasiveness, and poor prognosis.
- Accurate clinical diagnosis is critical for effective treatment and patient outcomes.
- Histopathological examination is the current gold standard for MPM diagnosis.
Purpose:
- To review commonly used and novel immunohistochemistry (IHC) markers for MPM.
- To highlight the role of IHC in the differential diagnosis of MPM.
- To provide a reference for clinicians in diagnosing and treating MPM.
Summary:
- Immunohistochemistry (IHC) serves as a crucial auxiliary method in the pathological diagnosis of malignant pleural mesothelioma (MPM).
- A combination of IHC markers, including established and novel ones, aids in differentiating MPM from metastatic pleural tumors.
- Utilizing specific positive and negative IHC markers assists in differential diagnosis, guiding treatment strategies.
Impact:
- Enhanced diagnostic accuracy for malignant pleural mesothelioma.
- Improved differential diagnosis between MPM and other pleural malignancies.
- Provides a valuable resource for clinicians in the diagnosis and management of MPM.
